1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Pharmion Acquires Cabrellis Pharmaceuticals

M&A Deal Summary

Pharmion Acquires Cabrellis Pharmaceuticals

On November 16, 2006, Pharmion acquired life science company Cabrellis Pharmaceuticals for 59M USD

Acquisition Highlights
  • This is Pharmion’s 1st transaction in the Life Science sector.
  • This is Pharmion’s largest (disclosed) transaction.
  • This is Pharmion’s 1st transaction in the United States.
  • This is Pharmion’s 1st transaction in California.

M&A Deal Summary
Date 2006-11-16
Target Cabrellis Pharmaceuticals
Sector Life Science
Buyer(s) Pharmion
Deal Type Add-on Acquisition
Deal Value 59M USD

Target

Cabrellis Pharmaceuticals

San Diego, California, United States
Cabrellis Pharmaceuticals Corp. is a developer of third-generation synthetic anthracycline for small-cell lung cancer.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Pharmion

Boulder, Colorado, United States
Category Company
Founded 1999
Sector Life Science
Employees166
DESCRIPTION

Pharmion Corporation is a global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza®, a DNA demethylating agent.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2006 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Solution for

Product

Company

Legal